Ascendis Pharma AS
$ 249.84
0.52%
14 Apr - close price
- Market Cap 15,259,269,000 USD
- Current Price $ 249.84
- High / Low $ 250.27 / 244.81
- Stock P/E N/A
- Book Value -3.11
- EPS -4.40
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.07 %
- ROE -8.18 %
- 52 Week High 250.74
- 52 Week Low 150.89
About
Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.
Analyst Target Price
$295.48
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-11 | 2025-11-06 | 2025-08-07 | 2025-05-01 | 2025-02-12 | 2024-11-14 | 2024-09-03 | 2024-05-02 | 2024-02-07 | 2023-11-07 | 2023-09-05 | 2023-04-27 |
| Reported EPS | -0.55 | -1 | -0.64 | -1.58 | -0.64 | -1.72 | -2.11 | -2.3 | -1.54 | -2.88 | -2.16 | -1.98 |
| Estimated EPS | -0.15 | -0.28 | -1.31 | -1.51 | -0.93 | -1.49 | -1.46 | -1.5 | -2.03 | -2.38 | -2.59 | -2.66 |
| Surprise | -0.4 | -0.72 | 0.67 | -0.07 | 0.29 | -0.23 | -0.65 | -0.8 | 0.49 | -0.5 | 0.43 | 0.68 |
| Surprise Percentage | -266.6667% | -257.1429% | 51.145% | -4.6358% | 31.1828% | -15.4362% | -44.5205% | -53.3333% | 24.1379% | -21.0084% | 16.6023% | 25.5639% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.3 |
| Currency | EUR |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ASND
2026-04-12 19:10:03
Ascendis Pharma A/S (NASDAQ:ASND) announced plans to list its ordinary shares directly on The Nasdaq Global Select Market, effective April 20, with all ADSs converting to ordinary shares. The company also reported positive Week 52 data from its Phase 2 COACH trial for achondroplasia and that its TransCon CNP therapy, Yuviwel, received orphan drug exclusivity and is now commercially available in the U.S.
2026-04-12 11:39:28
Ascendis Pharma recently announced positive Phase 2 COACH trial data for its TransCon CNP and TransCon hGH combination, showing improved growth and other metrics in children with achondroplasia. Concurrently, the company secured U.S. orphan drug exclusivity for YUVIWEL until 2033 and has begun its commercial launch, bolstering its rare-disease presence. These developments strengthen Ascendis Pharma's investment narrative, with analysts projecting significant revenue and earnings growth, leading to a fair value estimate showcasing a potential upside.
2026-04-09 10:10:49
RBC Capital has reaffirmed its Buy rating for Ascendis Pharma A/S (ASND.US), maintaining a target price of $275. Analyst Luca Issi, despite a past year success rate of 36.8% and an average return of -3.9%, sees continued potential in the company. This rating is based on analysis data provided by TipRanks.
2026-04-09 10:10:49
Ascendis Pharma A/S announced its plan to directly list its ordinary shares on Nasdaq, effective April 20, 2026. This transition involves exchanging all outstanding American Depositary Shares (ADSs) for ordinary shares at a one-to-one ratio. The company anticipates that this direct listing will broaden access for global investors and potentially enhance institutional ownership and trading liquidity by facilitating inclusion in certain equity indexes.
2026-04-08 22:09:31
Ascendis Pharma A/S is transitioning from American Depositary Shares (ADSs) to a direct listing of its ordinary shares on The Nasdaq Global Select Market, effective April 20, 2026, under its existing "ASND" ticker. All outstanding ADSs will be mandatorily converted to ordinary shares on a one-for-one basis, with April 17, 2026, being the last trading day for ADSs. The company filed a Form 6-K detailing this change, emphasizing that holders through DTC will automatically receive ordinary shares.
2026-04-08 22:09:31
Ascendis Pharma (Nasdaq: ASND) announced it will directly list its ordinary shares on The Nasdaq Global Select Market starting April 20, 2026. All existing American Depositary Shares (ADSs) will be exchanged for ordinary shares on a 1-for-1 basis, continuing to trade under the ASND ticker. This move aims to increase investor access, facilitate potential index inclusion, and improve institutional ownership and liquidity.
